Dr Thomas Kronbach
BioCrea turns concepts into drug candidates. BioCrea is creating new drugs for the treatment of debilitating diseases of the central nervous system. With industry background and an international leadership team BioCrea provides new, first-in-class drug candidates for pharmaceutical companies.
BioCrea’s ability in inventing new treatments led to partnerships with Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. They validate the company’s technology.
BioCrea is ideally positioned to provide new CNS drugs. Unique expertise and technology was integrated at BioCrea to generate new treatments. BioCrea’s patient-to-screen platform combines patient derived genetic information with the screening process and thus makes the outcome less dependent on biological hypothesis of CNS diseases.
